Xenon Pharmaceuticals
XENE
66 hedge funds and large institutions have $245M invested in Xenon Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 19 increasing their positions, 14 reducing their positions, and 3 closing their positions.
400% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 3
69% more capital invested
Capital invested by funds: $145M → $245M (+$100M)
36% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 14
22% more funds holding
Funds holding: 54 → 66 (+12)
9.87% more ownership
Funds ownership: 62.44% → 72.3% (+9.9%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.57M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$4.1M |
| 3 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$2.26M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$2.26M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$2.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.31M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$861K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$728K |
| 4 |
Squarepoint
New York
|
-$579K |
| 5 |
AA
ALPS Advisors
Denver,
Colorado
|
-$463K |
XENE Hedge Fund Activity: Q4 2019 in Review
66 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2019, worth a combined $245M — up 69% from $145M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new XENE positions and 3 closed out — a net gain of 12 holders — while 19 added to existing stakes and 14 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $6.57M. The largest seller was BlackRock, exiting entirely with an estimated $2.31M sold.
- 66 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2019, up from 54 in Q3 2019.
- Funds reported $245M of Xenon Pharmaceuticals stock for Q4 2019, up 69% quarter-over-quarter.
- 15 funds opened new Xenon Pharmaceuticals positions in Q4 2019 and 3 closed out, a net change of +12 holders.
- The largest Xenon Pharmaceuticals buyer in Q4 2019 was Adage Capital Partners, an estimated $6.57M added.
- The largest Xenon Pharmaceuticals seller in Q4 2019 was BlackRock, an estimated $2.31M sold.
Based on aggregated 13F filings for Q4 2019.